Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of IgA Antibody Titer Induced by Human-Bovine Rotavirus Candidate Vaccine with Bovine Rotavirus and Rotarix.

Archives of Razi Institute·2023
Same author

Oncolytic Newcastle disease virus effects on immune response - a new issue in cancer treatment.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2023
Same author

Characterization and Comparison of Mesenchymal Stem Cell-Derived Exosome Isolation Methods using Culture Supernatant.

Archives of Razi Institute·2023
Same author

Phenolic composition of ten plants species used as ethnoveterinary medicines in Omusati and Kunene regions of Namibia.

Scientific reports·2022
Same author

Comparison of the Effect of Adipose Mesenchymal Stem Cells-Derived Secretome with and without Reovirus in CT26 Cells.

Archives of Razi Institute·2022
Same author

The nutritional use of millet grain for food and feed: a review.

Agriculture & food security·2021

Related Experiment Video

Updated: May 14, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

HSP70 modified response against HPV based tumor.

M Farzanehpour1, H Soleimanjahi, Z M Hassan

  • 1Department of Virology, School of Medicine, Tarbiat Modares University, Tehran, Iran.

European Review for Medical and Pharmacological Sciences
|February 5, 2013
PubMed
Summary

Heat-shock protein 70 (HSP70) acts as an effective adjuvant, significantly boosting immune responses against tumors when co-administered with DNA vaccines. This approach enhances anti-tumor immunity and reduces tumor size in treated mice.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Related Experiment Videos

Last Updated: May 14, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Area of Science:

  • Immunology
  • Oncology
  • Vaccine Development

Background:

  • DNA immunization introduces plasmid DNA encoding antigens for vaccination.
  • Therapeutic vaccination targets oncogenes like E7 for cancer treatment.
  • Adjuvants are crucial for enhancing vaccine-induced immune responses.

Purpose of the Study:

  • To investigate the impact of co-delivering Heat-shock protein 70 (HSP70) with a DNA vaccine targeting HPV-E7.
  • To evaluate the enhancement of cellular immune responses and anti-tumor protection.
  • To assess HSP70's potential as an adjuvant in DNA vaccination.

Main Methods:

  • Intramuscular injection of mixed DNA constructs (pcDNA/E7 + HSP70).
  • Evaluation of E7-specific cellular immune responses (CTL).
  • Assessment of tumor size reduction in tumor-bearing mice.

Main Results:

  • The DNA vaccine significantly influenced E7-specific CTL responses compared to controls.
  • Co-delivery of pcDNA/E7 + HSP70 generated stronger immune responses.
  • Treatment with pcDNA/E7 + HSP70 significantly decreased tumor sizes.

Conclusions:

  • Co-administration of pcDNA/E7 + HSP70 was more immunologically effective than pcDNA/E7 alone.
  • HSP70 exhibits potent adjuvant activity, enhancing E7-specific immune responses.
  • HSP70-based vaccines show promise for future cervical cancer immunotherapy.